Southpoint-linked Form 4: 67,114 FENC shares sold Oct 7–9, 2025
Rhea-AI Filing Summary
Fennec Pharmaceuticals (FENC) insiders filed a Form 4 reporting multiple open-market sales of common stock across 10/07/2025 to 10/09/2025
Reporting entities tied to Southpoint (Southpoint Capital Advisors LP/LLC, Southpoint GP entities and John S. Clark II) sold a total of 67,114 shares in three tranches at weighted-average prices of approximately $9.5871, $9.4732, and $9.3461. Reported beneficial ownership after each trade was 4,050,314, 4,030,709, and 4,010,100 shares respectively. The filing explains that the shares are held directly by Southpoint Master Fund, LP and that the reporting persons disclaim beneficial ownership except for pecuniary interest.
Positive
- Timely disclosure of insider sales filed on 10/09/2025
- Detailed execution notes provide weighted-average prices and offer to supply trade-level detail on request
Negative
- Substantial insider selling: total of 67,114 shares sold across three days
- Decline in reported beneficial ownership to 4,010,100 shares by 10/09/2025
Insights
Large, disclosed insider sales by a 10% beneficial group; filing shows standard disclaimers.
The filings show the Southpoint group executed multiple open-market sales totaling 67,114 shares over three days ending on 10/09/2025
These sales were reported under the investment-manager/general-partner structure and include the customary disclaimer of beneficial ownership except for pecuniary interest. Monitor subsequent Form 4s for further reductions or any director-level sales that change board alignment within the next 30–90 days.
Sales occurred at prices near $9.35–$9.59, likely modest market impact given multi-day execution.
Transaction notes state each tranche was executed in multiple trades with reported weighted-average prices of $9.5871, $9.4732, and $9.3461
If these represent liquidation of fund holdings, watch volume and share-price movements in the days around 10/07/2025–10/09/2025 and any further disclosures of sales or transfers within the next quarter.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 20,609 | $9.3461 | $193K |
| Sale | Common Stock | 19,605 | $9.4732 | $186K |
| Sale | Common Stock | 26,900 | $9.5871 | $258K |
Footnotes (1)
- The securities are directly held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. The transaction was executed in multiple trades at prices ranging from $9.47 to $9.70. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. The transaction was executed in multiple trades at prices ranging from $9.31 to $9.61. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. The transaction was executed in multiple trades at prices ranging from $9.30 to $9.42. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.